Biotechnology
featured
NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
» Read More
More
-
Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.
-
Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
-
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
-
Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.
-
The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.
-
Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.
-
Discussing the early trial results of the next-generation cholesterol lowering drugs, with Tony Butler, Barclay's managing director/pharmaceuticals analyst.
-
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
-
Jay Flatley, Illumina CEO, discusses fending off Roche's unsolicited bid as well as the future of his company.
-
The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.
-
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
-
Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.
-
CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.
-
Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.
-
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.
-
Find out why he’s bullish on this biotech name.
-
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
-
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
-
The biotech industry is off to its best start in over a decade. What's driving the accelerated growth? CNBC's Seema Mody has the details on speculative buyout targets this year.
-
Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.